The United Kingdom and the United States have signed a important bilateral deal that will preserve zero tariffs on British drug products entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the NHS. This move ensures that duties on these key goods will stay at zero for a duration of 36 months.
This development comes after earlier warnings to dramatically increase tariffs on branded pharmaceutical products, with figures floated up to double the cost.
"This agreement with the Britain strengthens the global environment for new treatments and brings much-needed fairness to American-British pharmaceutical trade," a release declared.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the America, which is clearly the biggest destination for major UK drugmakers.
Export figures show that in the year prior to September, the UK sold drugs valued at £11.1bn to the US. This amount made up a significant portion of all goods exports in that period.
"This deal protects employment, boosts funding and sets the stage for the UK to establish itself as a international leader for medical research," a government official remarked.
Key UK Commitments
The deal includes several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to raise total health service expenditure on drugs from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to control costs will be capped at 15%. In the past, rebates exceeded 20%.
Recent Tensions
The deal takes place against a protracted row between the sector and the UK government over drug pricing and regulatory access.
These tensions were exacerbated by assertions that American patients were charged significantly more for the identical medicines than people in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while major investments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the last ten years.
